Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Journal Name
Leukemia & Lymphoma
Primary Author
Tanasijevic, AM
Author(s)
Anna M Tanasijevic, Anna Revette, Heidi D Klepin, Amer Zeidan, Danielle Townsley, Courtney D DiNardo, Marie Sebert, Amy E DeZern, Richard M Stone, Emily S Magnavita, Richard Chen, Mikkael A Sekeres, Gregory A Abel
Original Publication Date

The anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count. Symptoms of anemia are fatigue and tiredness. of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin: A protein in the red blood cells. Hemoglobin picks up oxygen in the lungs and brings it to cells in all parts of the body. (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.